https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44977 Wed 26 Oct 2022 08:54:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42531 Wed 24 Aug 2022 15:22:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30111 Wed 11 Apr 2018 14:16:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17059 Wed 11 Apr 2018 09:27:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36334 0.05) at each sampling day. At day 7 post-transplant, 85.7% and 79.5% of the observed plasma concentrations were outside the recommended therapeutic range for obese and non-obese patients respectively, at day 30, 52.9% and 57.4%, and at 6 months, 18.7% and 27.5%. Conclusion: In the first week post-transplant, tacrolimus trough concentrations after standard mg/kg dosing post liver transplant appear to be corrected by total bodyweight. Obese patients have a similar number of trough plasma concentrations outside the therapeutic range compared to non-obese patients.]]> Wed 06 Apr 2022 14:03:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45654 Wed 02 Nov 2022 15:37:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52914 Wed 01 Nov 2023 09:30:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37180 Wed 01 Mar 2023 11:52:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47644 Tue 24 Jan 2023 14:44:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41921 p = 0.0007). Studies of other clinical decision support systems and heparin monitoring systems did not demonstrate improved safety, and quality findings were inconsistent. Systematic education and feedback programs were not efficacious. Conclusions: There is currently insufficient high-quality evidence to recommend any reviewed intervention, though several warrant closer evaluation. Adequately powered controlled trials assessing safety outcomes and evidence-based quality markers in high-risk patient groups and studies of interventions to improve safety of LMWH and DOAC prescribing are needed.]]> Tue 16 Aug 2022 09:02:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48282 Tue 14 Mar 2023 11:24:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54779 Tue 12 Mar 2024 11:04:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29674 Thu 21 Oct 2021 12:51:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48437 Thu 16 Mar 2023 14:25:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47209 Thu 15 Dec 2022 16:04:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34468 Thu 09 Dec 2021 11:03:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32799 Thu 09 Dec 2021 11:02:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52234 Thu 05 Oct 2023 11:39:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48125 Thu 02 Mar 2023 15:06:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30194 n = 110) and non-Indigenous women (n = 105), frequency matched on age and remoteness. We used Pearson’s Chi-squared analysis to compare proportions, hazard models to assess survival differences and calculated disability-adjusted life years (DALYs). Results: Indigenous women were more likely to be socially disadvantaged (43 vs. 20 %, p < 0.01) have comorbidity (42 vs. 18 % p < 0.01), and have regional spread or distant metastasis (metastasis, 51 vs. 36 %, p = 0.02) than non-Indigenous women; there was no difference in treatment patterns. More Indigenous women died in the follow-up period (p = 0.01). DALY’s were 469 and 665 per 100,000 for Indigenous and non-Indigenous women, respectively, with a larger proportion of the burden attributed to premature death among the former (63 vs. 59 %). Conclusions: Indigenous women with breast cancer received comparable treatment to their non-Indigenous counterparts. The higher proportion of DALYs related to early death in Indigenous women suggests higher fatality with breast cancer in this group. Later stage at diagnosis and higher comorbidity presence among Indigenous women reinforce the need for early detection and improved management of co-existing disease.]]> Sat 24 Mar 2018 07:41:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27289 Sat 24 Mar 2018 07:40:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28464 Sat 24 Mar 2018 07:39:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28531 Sat 24 Mar 2018 07:28:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23319 Sat 24 Mar 2018 07:13:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26160 Mon 22 Jul 2019 13:58:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46209 Mon 14 Nov 2022 11:43:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47953 Mon 13 Feb 2023 14:06:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54731 Mon 11 Mar 2024 14:12:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31928 Mon 09 Apr 2018 08:51:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36056 Mon 03 Feb 2020 11:52:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45500 Fri 28 Oct 2022 16:00:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42101 n = 125) and Non‐Indigenous (n = 125) Australian adults diagnosed with cancer. Descriptive statistics were used to compare type and prevalence of 24 need items measured by the SCNS‐SF34 and SCNAT‐IP. Results: A higher proportion of Non‐Indigenous participants compared to Indigenous participants reported having any moderate‐to‐high level of unmet needs (70% vs. 54%, p = 0.013) and the difference was consistently observed across non‐matched characteristics. While concerns for caregivers, fear of recurrence and pain were central needs for both Indigenous participants and Non‐Indigenous participants, there were some key differences in the specific unmet needs between groups. Physical issues including doing usual daily activities and dealing with fatigue were the top priorities for Non‐Indigenous people, while money worries, dealing with psychological issues such as how to keep their spirit strong or hope about their future appeared to be priorities for Indigenous people. Conclusions: Variations in the unmet supportive care needs between Indigenous and Non‐Indigenous people with cancer may guide health professionals to target specific needs when preparing care plans.]]> Fri 23 Jun 2023 08:45:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53882 0.872; correlation coefficient, r = 0.87, P < 0.0001). Conclusions: DBS provides an alternative sampling strategy for the TDM of many anticancer drugs. Further research is required to establish a standardized approach for sampling and processing DBS samples to allow future implementation.]]> Fri 19 Jan 2024 14:22:43 AEDT ]]>